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Abstract: Background and aim: To find if intra-operative local injection of Mitomycin-C after internal Urethrotomy in
patients with urethral stricture can improve the outcome of surgery. Materials and Methods: Seventy patients
were allocated in two groups randomly and data were analyzed. The case group (n=35) was treated by internal
Urethrotomy with intra-operative local injection of Mitomycin-C. The control group (n=35) was underwent stan-
dard internal Urethrotomy. The patients were followed after removing catheter and for 6 months after surgery by
USS PROM questionnaire and uroflowmetry. Results: A significant difference was observed in terms of urody-
namic indices like Q-max (p-value=0.006) and urine flow pattern (p-value=0.025) after internal Urethrotomy in
the local injection of Mitomycin-C group and control group, six months after surgery. In the case group, in the six
months after operation, only 2.9% of patients had Q-max less than 15 and no one had obstructive pattern, while
in the control group, 25.7% of patients had Q- max less than 15 and 17.1% had obstructive pattern. However,
the patient’s satisfaction history did not show any significant difference in post-internal Urethrotomy voiding
status in the local injection of Mitomycin-C group and control group, either immediately after removal of the
urethral catheter (p-value=1) and six months after surgery (p-value=0.198). Also, no significant difference was
observed in terms of urodynamic indices like Q-max (p-value=0.771) and urine flow pattern (p-value=1) after
internal Urethrotomy in the local injection of Mitomycin-C group and control group, immediately after removal
of the urethral catheter. Conclusions: Intra-operative local injection of Mitomycin-C after internal Urethrotomy
can be regarded as a safe and efficient technique which has several advantages including lower cost. Lower re-
currence rate of urethral stricture is the main effect of local Mitomycin-C application that is more prominent
after six months follow up.
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1. Introduction
Urethral stenosis is one of the oldest known urological dis-
orders as well as an unpleasant condition. It can be the re-
sult of trauma, catheterization, prostate surgeries, or even a
congenital occurrence (1-6). There are several ways to cure
this condition based on the location, size and cause of the
stenosis, in addition to the skilfulness of the surgeon. Di-
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latation, internal Urethrotomy, stent insertion, and Urethro-
plasty are some of the methods currently used throughout
the medical world (14,13,12,11,7,6,4,1,26). Furthermore, in
order to increase the effectiveness of the surgery and to de-
crease the potential recurrence rate of stenosis, CIC (Alter-
nating Conductive Catheterization) and/or hydraulic dilators
can be prescribed for patients to maximise post-surgery re-
sults (12,10,8,6,5,17). However, despite these efforts, a high
number of patients would experience the return of this con-
dition post-surgery. Due to this concern, the need for alter-
native procedures arises. As a result, the idea of using fibri-
nolytic materials to break down the scar or prevent it from
developing has been put forward. Thus, this paper aims to
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investigate the effects of local mitomycin-C, prescribed after
internal Urethrotomy, in the overall effectiveness of the oper-
ation and the improvement of the condition in patients with
stenosis.
2. Material and methods
In this randomized double blind clinical trial, a total number
of 70 patients diagnosed with urethral stenosis were studied
at Shohadaye Tajrish Hospital from June 2015 to June 2017.
The study included all those who are present and available to
be tracked throughout the project. It also required the candi-
dates to experience internal Urethrotomy (Urethral Stricture
length<1.5 cm), judging from their medical history, physi-
cal examination, and radiographic as well as cryptoscopic
findings. Patients with long stenosis, Penile Urethral stric-
ture, and other conditions such as BXO and BPH were not
be included. Patients underwent a comprehensive history
check (outlining their age, gender, reason for stenosis, and
previous occurrences of this condition), physical examina-
tion (identifying the location and length of stenosis as well as
the type(s) of previous surgeries), and radiographic studies
(in cases of anterior stenosis). Subsequently, they underwent
cystoscopy, anaesthesia, and a dorsal lithotomy position un-
der the internal star-like Urethrotomy. The patients then had
divided into two groups. One group, consisting of half of the
study population, will have sub-mucosal injection of 0.1mg
/ 2cc mitomycin-C with a 22-Gauge needle administered to
them. Then both groups were re-examined to identify poten-
tial differences. After the surgery, the catheter was implanted
for five days.
Thereafter, Patients were examined for symptoms and
uroflowmetry (6 months after the removal of the catheter).
In case of abnormal results (Q-Max<15 & Obstructive pat-
tern) RUG-VCUG and, if needed, urethrocystoscopy were
performed. Furthermore, the need for internal Urethrotomy
and dilatation was reviewed and, if needed, re-incision and
re-injection of mitomycin-C took place. For the purpose of
this paper, recovery was defined as patients’ ease in urination
and recurrence was defined as failure to resolve this condi-
tion.
3. Results
The average age of participants was 37.49 years (±2.483) in
the case group and 39.64 years (±2.448) in the control group.
The average length of stenosis was 0.8371 cm (±0.07219)
in the case group and 1.0886 cm (±0.12694) in the control
group. In the case group, there were 3 (8.6%), 23 (65.7%) and
9 (25.7%) cases of distal, mid and proximal bulbar, respec-
tively. While, in the control group, the number of distal, mid
and proximal bulbar cases were 5 (14.3%), 20 (57.1%) and 10
(28.6%), respectively. This showed no significant difference
between the two groups (p-value = 0.691) (Table 1).
19 cases (54.3%) in the case group and 23 cases (65.7%) in the
control group had a positive history of previous surgery. In
mentioning that, there was no statistically significant differ-
ence between the two groups (p-value = 0.227). Furthermore,
the status of the specimens, in terms of indicators for symp-
tom assessment and urofluorometry (Q-max and urine flow
pattern) immediately after surgery as well as 6 months after
the operation, were expressed as numbers and percentages
in both groups. Fisher statistical test showed that there was
no significant difference between the two groups in terms of
immediate postoperative index (p-value = 1) and six months
after the surgery index (p-value = 0.198) (Tables 3 and 4).
The two groups were investigated based on indicators for
symptom assessment immediately and 6 months after the
surgery. In the case group, 4 patients (3 with unknown
reasons and 1 due to previous surgeries) immediately after
the surgery and only 1 candidate (due to catheterization) 6
months after the operation, were unhappy with the results.
This was while, in the control group, 4 candidates (1 per-
son due to inflation, 1 person due to catheterization, 1 per-
son due to congenital causes, and the other patient due to
unknown reasons) immediately after the surgery and 5 pa-
tients (1 person due to inflation, 1 person due to catheteriza-
tion, 1 person due to congenital causes, and 2 patients due to
trauma) 6 months after the operation, were not satisfied with
the results.
When performed, Fisher statistical test showed that the two
groups did not exhibit any significant difference in their
uroflowmetry Q-max indexes immediately after surgery (p-
value = 0.771). While, there was a significant statistical dif-
ference between the uroflowmetry Q-max indexes of the two
groups in six months after surgery (p-value = 0.006) (Tables 5
and 6). Fisher statistical test showed that there was no signif-
icant statistical difference between the two groups in terms
of uroflowmetry pattern immediately after surgery (p-value
= 1). However, there was a significant statistical difference
between the two groups in terms of uroflowmetry index six
months after surgery (p-value = 0.025).
Patients who were dissatisfied either due to their post-
surgery symptoms or based on their uroflowmetric Q-max
>15 indexes, or those who experienced obstruction patterns,
were put to undergo RUG. Fisher statistical test showed that
the two groups had a significant statistical difference in RUG
index (p-value = 0.011). In saying that, the case group had
no difficulties in RUG, while 7 patients (20.0%) in the control
group experienced stenosis in the procedure. Of these 7, 2
had distal bulbar stenosis, 2 had mid-bulbar stenosis, and 3
had proximal bulbar stenosis.
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Table 1: Location of Stenosis in both groups
Location of Stenosis Case Group Control Group Total
Distal Bulbar 3(8/6%) 5(14/3%) 8(11/4%)
Mid Bulbar 23(65/7%) 20(57/1%) 43(61/4%)
Proximal Bulbar 9(25/7%) 10(28/6%) 19(27/1%)
Total 35(100%) 35(100%) 70(100%)
Table 2: Etiology of stricture in both groups
Reason of Stenosis Case Group Control Group Total
Infection 0(0%) 5(14/3%) 5(7/1%)
Trauma 9(25/7%) 11(31/4%) 20(28/6%)
Previous Surgery 3(8/6%) 4(11/4%) 7(10%)
Congenital 1(9/2%) 3(6/8%) 4(7/5%)
Previous Catheterization 6(17/1%) 5(14/3%) 11(15/7%)
Unknown 16(45/7%) 7(20%) 23(32/9%)
Total 35(100%) 35(100%) 70(100%)
Table 3: Patients’ Status Immediately After Surgery
Patients’ Status Immediately After Surgery Case Group Control Group Total
Satisfied 31(88/6%) 31(88/6%) 62(88/6%)
Not Satisfied 4(11/4%) 4(11/4%) 8(11/4%)
Total 35(100%) 35(100%) 70(100%)
Table 4: Patients’ Status 6 Months After Surgery
Patients’ Status Immediately After Surgery Case Group Control Group Total
Satisfied 34(97/1%) 30(85/7%) 64(91/4%)
Not Satisfied 1(2/9%) 5(14/3%) 6(8/6%)
Total 35(100%) 35(100%) 70(100%)
Table 5: Q-max Immediately After Surgery
Q-max Immediately After Surgery Case Group Control Group Total
≥ 15 27(77/1%) 28(80%) 55(78/6%)
< 15 8(22/9%) 7(20%) 15(21/4%)
Total 35(100%) 35(100%) 70(100%)
Table 6: Q-max 6 Months After Surgery
Q-max 6 Months After Surgery Case Group Control Group Total
≥ 15 34(97/1%) 26(74/3%) 60(85/7%)
< 15 1(2/9%) 9(25/7%) 10(14/3%)
Total 35(100%) 35(100%) 70(100%)
4. Discussion
Urethral stenosis may be due to biopsies, conduit manipula-
tion, catheterization, diathermy, external trauma, hypospa-
diasis surgery, radical prostatectomy, other prostate surg-
eries, congenital causes, or an unknown reason. (1,2,3,4,5,6)
During healing of the affected part of the urethra, extrava-
sation of the urinary sub-epithelium and the subsequent
scar tissue enlargement occur in the lumen and spongiofi-
brosis (1,4,5,7,8,9,10). A variety of methods are used to
treat stenosis. These can include ductal dilatation, inter-
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nal Urethrotomy, laser, stent placement, and open surgery
(1,4,6,7,11,12,13,14). The success rates of luminal dilatation,
Urethrotomy, laser, stent placement and open surgery are
60%, 50%, 56%, 40%, 90%, respectively (1,4,11,15,16). It is im-
portant to note that open surgeries cannot be done at all cen-
tres as they require high levels of expertise. In addition, the
most common method of treatment is internal Urethrotomy
and dilatation (4,10,12). The success rate of internal Urethro-
tomy is directly dependent on the length and extent of spon-
giofibrosis. In saying that, Internal Urethrotomy is used for
stenosis less than 1.5 cm in the bulbar ducts and the Penile. If
dilatation has been done for more than a year, more success
will be achieved (1). However, the low success rate and the
high rate of recurrence of stenosis despite the treatment, and
the need to maintain the Foley catheter, duct stent, and CIC
suggests the need for new methods (5,6,8,10,12,17). Corticos-
teroids (such as triamcinolone), traditional herbal remedies,
TGF-β, oligodioxy nucleotide, and recombinant adenovirus
have been used to prevent scarring (4,10,18,19,20,21,22). The
other method is the use of mitomycin (12). Mitomycin-C is
an antibiotic of Streptomyces caspitus origin that was dis-
covered in 1958 and has been clinically used since 1963 in
pterygium surgery. It also inhibits fibroblast proliferation,
collagen deposition, and scar formation (1,4,5,12). Due to
its antiproliferative and anti-scar effect of mitomycin-C, it
has been used in a wide range of medical fields and applica-
tions. Mitomycin-C is used in the treatments of stenosis and
scar formation in glaucoma trabeculectomy, pterygium, na-
solacrimal duct obstruction, otitis media myringotomy, up-
per airway stenosis (laryngeal and tracheal stenosis), vaginal,
anal, and conduit stenosis (5,8,12).
A study carried out by Dr. Mehdi Shirazi et al., in the field
of captopril gel injection after internal Urethrotomy, pub-
lished in 2007, found that 56 patients were 39.5 years of age
with a mean follow-up of 16 months. For follow-up, maxi-
mal urine flow and RUG were performed, and cystoscopy and
VCUG were completed as needed. The recurrence rate in the
group of patients receiving captopril gel was lower than that
of placebo group (8).
In a study by Dr. Hamid Mazdak et al., in the field of sub-
mucosal triamcinolone injection for bulbar stenosis, pub-
lished in 2010, it was reported that 55 patients were di-
vided into two groups. They then received symptoms and
RUG follow-ups and if needed, Urethroscopy for 13.7 months
(±5.5). Consequently, 21.7% of the patients after the triamci-
nolone injection and 50% of the control group candidates did
not experience stenosis recurrence (10).
A review study by Dey et al., in India on the causes and treat-
ments of common anterior stenosis, published in 2014, the
topic of sub-mucosal injection of mitomycin-C is put for-
ward and further explored. In this paper, the results showed
that the risk of restenosis was reduced to 10% after the in-
jection of mitomycin-C. While in the internal Urethrotomy
alone 50% recurrence was reported during the 6-month pe-
riod of follow-ups (1). A study by Ali Ayyildiz et al., in Turkey,
which investigated the effect of mitomycin-C injections on
the treatment of rat stenosis fibrosis and its results were pub-
lished in 2004, reports that despite its toxic nature at high
doses, mitomycin-C exhibits antifibrotic effects at low doses
(4).
In a study performed by Vanni et al., in Massachusetts, in the
field of intrathecal injection of mitomycin-C after Urethro-
tomy, published in 2011, it has been reported that after 12
months of follow-up with uroflowmetry, PVR determination,
and flexible cystoscopy, of the 18 patients with bladder steno-
sis, 72% did not develop urethral stenosis again after 1 injec-
tion of mitomycin-C and 89% after two injections (12).
A 2015 multicentre Redshaw study in the United States, pub-
lished in the Journal of Urology, examined the efficacy of
mitomycin-C injections after bladder neck incision in 66 pa-
tients with 3-month cystoscopic follow-ups. It was con-
cluded that this effect is less than that suggested in the previ-
ous studies and side effects have been observed in 7% of the
cases (23).
In Farrell’s studies in 2015 and Ryan’s in 2017, local injections
of mitomycin-C were made after internal Urethrotomy and
were followed by CIC, and patients underwent urodynamic
and cystoscopic examinations at 1, 3, 6, and 12 months.
The results indicated that local injection of mitomycin-C and
subsequent CIC can be considered as a safe, effective and ac-
cessible method for short, recurrent, and complicated bul-
bomembranous and bulbar stenosis (24,25).
5. Conclusion
It can be concluded that the injection of mitomycin-C into
the stenosis after internal Urethrotomy can be considered as
an effective and safe method of reducing the recurrence of
this condition. The results of this injection in reducing the
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